PRESS RELEASE published on 02/26/2025 at 07:30, 1 year 5 months ago BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division BRAIN Biotech AG reports 11% organic growth in Q1 of FY 24/25 for BRAINBiocatalysts, forecasts strong growth and solid EBITDA margin, maintains strong cash position of €17.8 million Financial Results EBITDA Margin Organic Growth BRAIN Biotech AG BRAINBiocatalysts
BRIEF published on 02/13/2025 at 09:19, 1 year 5 months ago BRAIN Biotech s'associe au groupe PX pour le recyclage biologique de l'or Collaboration Recyclage Biologique BioXtracteur V2 Exploitation Minière Urbaine PX Or Durable
BRIEF published on 02/13/2025 at 09:19, 1 year 5 months ago BRAIN Biotech Partners with PX Group for Biological Gold Recycling Collaboration Biological Recycling BioXtractor V2 PX Urban Mining Sustainable Gold
PRESS RELEASE published on 02/13/2025 at 09:14, 1 year 5 months ago Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative for biological gold recycling, producing BioGold nuggets from local waste. Focus on sustainability Sustainability BRAIN Biotech AG PX Group Urban Mining Initiative Gold Recycling
BRIEF published on 01/15/2025 at 07:35, 1 year 6 months ago BRAIN Biotech AG maintient une solide position de trésorerie malgré un exercice 2023/24 difficile Résultats Financiers Perspectives De Croissance Stabilité Des Revenus Situation De Trésorerie Transactions Stratégiques
BRIEF published on 01/15/2025 at 07:35, 1 year 6 months ago BRAIN Biotech AG Maintains Strong Cash Position Amidst Challenging FY 2023/24 Financial Results Cash Position Strategic Transactions Growth Prospects Revenue Stability
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 6 months ago Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects BRAIN Biotech AG reports strong cash position & growth prospects in Annual Report 2023/24. Closed milestone transactions with Royalty Pharma & Akribion Therapeutics Cash Position Annual Report Growth Prospects BRAIN Biotech AG Milestone Transactions
BRIEF published on 12/12/2024 at 09:05, 1 year 7 months ago BRAIN Biotech AG Refocuses on Profitable Growth Profitable Growth Financial Forecast Strategic Initiatives BRAIN Biotech Enzyme Business
BRIEF published on 12/12/2024 at 09:05, 1 year 7 months ago BRAIN Biotech AG se recentre sur une croissance rentable Croissance Rentable Prévisions Financières CERVEAU Biotechnologie Initiatives Stratégiques Entreprise D'enzymes
PRESS RELEASE published on 12/12/2024 at 09:00, 1 year 7 months ago BRAIN Biotech AG Sharpens Focus on Profitable Growth BRAIN Biotech AG sharpens focus on profitable growth by creating new growth segment BRAINBiocatalysts. Targets include EUR 100 million revenues, 15% adjusted EBITDA margin, and high R&D ratio Profitable Growth Financial Forecast BRAIN Biotech AG Enzyme Business BRAINBiocatalysts
Published on 08/05/2026 at 23:40, 1 hour 40 minutes ago Galantas Gold Secures Key Permitting Approvals for Andacollo Gold Project
Published on 08/05/2026 at 23:10, 2 hours 10 minutes ago Ur-Energy Announces Date for Second Quarter 2026 Results and Conference Call and Webcast
Published on 08/05/2026 at 23:01, 2 hours 19 minutes ago Full Circle Lithium Announces Extension of Current Private Placement
Published on 08/05/2026 at 23:00, 2 hours 20 minutes ago Pentagon I Capital Corp. Announces Filing of Filing Statement with Respect to Its Qualifying Transaction
Published on 08/05/2026 at 22:35, 2 hours 45 minutes ago Cielo Selects Amdocs to Bring Intelligent Connectivity to Its Entire Brazilian Payment Terminal Network
Published on 08/05/2026 at 23:23, 1 hour 56 minutes ago EQS-Adhoc: Enapter AG: Agreement with Patrimonium to discharge corporate bond liabilities of around EUR 26 million; realignment to an asset-light business model; capital measure planned
Published on 08/05/2026 at 23:04, 2 hours 16 minutes ago AUTODOC to publish H1 2026 report and host a conference call on Q2 results on 13 August 2026
Published on 08/05/2026 at 19:14, 6 hours 6 minutes ago 2CRSi informe le marché sur la gouvernance de la société AETHER Infrastructures et l’avancement du projet AETHER auquel 2CRSi participe comme membre du consortium
Published on 08/05/2026 at 19:14, 6 hours 6 minutes ago 2CRSi informs the market about the governance of AETHER Infrastructures and the progress of the AETHER project in which 2CRSi takes part as a member of the consortium
Published on 08/05/2026 at 18:00, 7 hours 20 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2026
Published on 08/05/2026 at 18:00, 7 hours 20 minutes ago Information concerning the total number of voting rights and shares in the share capital as of July 31, 2026
Published on 08/05/2026 at 17:49, 7 hours 30 minutes ago Mersen : nombre d'actions et de droits de vote au 31 juillet 2026
Published on 08/05/2026 at 17:49, 7 hours 30 minutes ago Mersen: Number of shares and voting rights as of July 31, 2026
Published on 08/05/2026 at 17:45, 7 hours 35 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
